| 书目名称 | Personalized Pathway-Activated Systems Imaging in Oncology | | 副标题 | Principal and Instru | | 编辑 | Tomio Inoue,David Yang,Gang Huang | | 视频video | | | 概述 | Elucidates the benefits and pitfalls of current clinic FDG PET.Enriches understanding of moving radiopharmaceuticals from the workbench to the clinic.Provides translational research for clinical discu | | 图书封面 |  | | 描述 | .This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed..Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agentshave potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome..This book serves as a reference for moving the discovery and development of radiopharma | | 出版日期 | Book 2017 | | 关键词 | Radiopharmaceutical; Theranostic; Personalized treatment; FDG PET; Nuclear biomarker; Nuclear imaging | | 版次 | 1 | | doi | https://doi.org/10.1007/978-981-10-3349-0 | | isbn_softcover | 978-981-10-9850-5 | | isbn_ebook | 978-981-10-3349-0 | | copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor |
The information of publication is updating
|
|
发表于 2025-3-21 17:18:54
